19:42 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest inhibiting the β amyloid - EPHB2 interaction could help treat AD. In a mouse model of AD, intrahippocampal injection of a peptide inhibitor of the β amyloid-EPHB2 interaction...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms MicroRNA and small interfering RNA combination therapy for cancer Mouse and cell culture studies suggest combined use of miRNA and siRNA against a target could...
07:00 , Sep 29, 2011 |  BC Innovations  |  Targets & Mechanisms

Subtyping lessons in brain cancer

A team at St. Jude Children's Research Hospital believes a screening approach based on disease subtypes will be important for identifying therapeutics for brain cancer patients. As a proof of principle, the researchers conducted a...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Anxiety EPH receptor B2 (EPHB2); FK506 binding protein 5 (FKBP5) Studies in mice suggest that inhibiting EPHB2 or FKBP5 could help...
08:00 , Feb 28, 2011 |  BioCentury  |  Strategy

Gilead's cancer encore

Gilead Sciences Inc. 's initial dalliance with cancer ended in 2001 when it sold its portfolio of liposomal chemotherapeutics. A decade later, the company is jumping back in, this time by acquiring companies with targeted...
08:00 , Dec 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) EPH receptor B2 (EPHB2); b-amyloid (Ab) Studies in patient samples and in mice suggest that agonizing EPHB2 could...
07:00 , Aug 5, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of ependymoma A new mouse model could help identify therapies for CNS tumors. Mice implanted with embryonic cerebral neural stem cells deficient in...
07:00 , Jul 19, 2010 |  BioCentury  |  Product Development

Selectively seeking SYK

CGI Pharmaceuticals Inc. has created a preclinical library of SYK inhibitors for rheumatoid arthritis and other inflammatory diseases that it believes are best in class because they are more selective than competing compounds in the...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

CGI, Gilead deal

Gilead will acquire CGI (formerly Cellular Genomics Inc. ) for up to $120 million in cash. An undisclosed majority of the payment will be paid up front, with the remainder to be paid upon clinical...
08:00 , Dec 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Adenomatous polyps EPH receptor B2 (EPHB2); ABL tyrosine kinase (ABL; ABL1; c-ABL) A study in mice suggests that inhibiting EPHB2 or its downstream effector,...